RAD51predict, a multi-centric research project for federated data governance
RAD51predict is a research project that evaluates RAD51 test as a predictive tool to improve diagnosis, classify tumors and help guide treatment decision-making. Genomcore provides a secure and compliant federated data repository to store and analyze multimodal datasets within the project.
About
The Vall d’Hebron Institute of Oncology (VHIO) has positioned itself as one of the most important comprehensive centers in Europe capable of transforming, in record time, the latest research discoveries in the laboratory to clinical practice. Located in Barcelona (Spain). VHIO collaborates closely with the Vall dHebron University Hospital’s Oncology Department, driven by a shared determination to both advance and accelerate personalized and targeted therapies against cancer.
Project
Empowering oncology breakthroughs: a collaborative data ecosystem for cancer research
The complexity of cancer research demands a paradigm shift towards large-scale, international collaborations, uniting diverse expertise to accelerate breakthroughs. Initiatives like those involving the Vall d'Hebron Institute of Oncology (VHIO) exemplify this vital trend, bringing together dedicated professionals to tackle the multifaceted challenges of the disease.
The project supports the integration and harmonization of data across different sources, while also ensuring that data is findable, accessible, interoperable, and reusable in compliance with FAIR principles (Findability, Accessibility, Interoperability, and Reuse). By establishing clear data formats, security protocols, and ethical guidelines, researchers – including oncologists, geneticists, and bioinformaticians – can confidently contribute their unique datasets and insights. According to Serra, the RAD51 test manages to predict the response to the PARP inhibitors in up to 95% of the cases in comparison to the 67% of HRR gene mutations and 71% of HRD genomics analyses.
Genomcore's platform offers a secure and compliant environment for managing diverse datasets generated by institutions like VHIO and their partners. By streamlining data integration, standardization, and analysis, we empower cancer research professionals to work more efficiently and effectively.
"Participating in this trial will be a great opportunity for patients with germline BRCA1/2 alterations and will allow us to demonstrate in clinical practice the efficacy of using the RAD51 test to identify patients without genetic alterations who may benefit from these drugs".
We are certified with ISO/IEC standards 27001:2013, 27017:2020 and 27018:2020, ensuring compliance with applicable data protection laws and regulations including GDPR and HIPAA. Genomcore’s Biomed platform guarantees ethical surveillance to ensure that the required international and national regulatory approvals are obtained to coordinate the data acquisition, storage and sharing.
